
The present study by Van Dyck and colleagues reports the encouraging results of an 18-month, phase 3 trial of lecanemab that involved participants with early Alzheimer’s disease. The primary endpoint was the change from baseline in the score on the Clinical Dementia Rating–Sum of Boxes. Key secondary endpoints were the change from baseline in amyloid burden as assessed by means of positron emission tomography, the score on the 14-item cognitive subscale of the Alzheimer’s Disease Assessment Scale, the Alzheimer’s Disease Composite Score, and the score on daily living scale of the Alzheimer’s Disease Cooperative Study–Activities.
Like
Save
Share